This is a routine conference presentation with no new data or catalysts. Monitor for PIONEER-1 trial enrollment updates or future data readouts for material stock-moving events.
Price Chart
Executive Summary
Oculis announced a presentation at Clinical Trials at the Summit 2026 on its lead candidate Privosegtor, a peptoid small molecule for optic neuritis. The presentation covers the PIONEER registrational program, which follows positive Phase 2 ACUITY data and Breakthrough Therapy/PRIME designations. This is a routine pipeline update with no new clinical data or regulatory decision, making it a low-impact event.
Key Facts
- Presentation at Clinical Trials at the Summit 2026 on June 13, 2026, by CEO Riad Sherif.
- Privosegtor has Breakthrough Therapy designation from FDA and PRIME designation from EMA for optic neuritis.
- PIONEER registrational program includes two trials in optic neuritis and one in NAION.
- No new clinical data or regulatory milestones announced in this press release.
Financial Impact
No financial data disclosed; routine pipeline update.
Risk Factors
- Clinical trial failure or regulatory setback for Privosegtor.
- Competition from other neuroprotective therapies in development.
- Dependence on single lead candidate for near-term value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 6-K | $8.76 $8.66 | ▼ −1.14% | ▼ −2.44% | $7.83 (−10.62%) |
Aug 10, 2026 11w ago | 6-K | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Aug 10, 2026 11w ago | Press Release | $12.76 $13.14 | ▲ +2.98% | ▲ +3.02% | $7.83 (−38.64%) |
Jun 11, 2026 19w ago | Press Release | $11.00 $11.30 | ▲ +2.73% | ▲ +2.29% | $7.83 (−28.82%) |
Jun 9, 2026 20w ago | Press Release | $10.98 $11.61 | ▲ +5.74% | ▲ +3.33% | $7.83 (−28.69%) |
May 29, 2026 21w ago | Press Release | $22.71 $11.21 | ▲ +50.63% | ▲ +48.10% | $7.83 (+65.51%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 11, 2026 24w ago | Press Release | $30.41 $28.07 | ▼ −7.69% | ▼ −7.77% | $7.83 (−74.25%) |
May 7, 2026 24w ago | Press Release | $31.09 $31.37 | ▲ +0.90% | ▼ −0.60% | $7.83 (−74.82%) |
May 5, 2026 25w ago | Press Release | $27.75 $30.41 | ▲ +9.59% | ▲ +7.60% | $7.83 (−71.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers